Hereditary episodic ataxia

Hereditary episodic ataxia (EA) refers to a group of rare inherited neurological disorders characterized by recurrent episodes of impaired coordination (ataxia), often accompanied by other neurological symptoms. These conditions primarily affect the nervous system, particularly the cerebellum, which is the brain region responsible for coordinating movement and balance. During episodes, individuals may experience severe imbalance, slurred speech (dysarthria), vertigo, nausea, and involuntary eye movements (nystagmus). Episodes can last from seconds to hours depending on the specific subtype and may be triggered by physical exertion, emotional stress, sudden movements, caffeine, or alcohol. Several subtypes of episodic ataxia have been identified, with Episodic Ataxia Type 1 (EA1) and Episodic Ataxia Type 2 (EA2) being the most common and best characterized. EA1 is caused by mutations in the KCNA1 gene encoding a potassium channel and is associated with brief episodes of ataxia lasting seconds to minutes, often accompanied by myokymia (continuous muscle rippling). EA2 is caused by mutations in the CACNA1A gene encoding a calcium channel and typically presents with longer episodes lasting hours, often with interictal nystagmus and progressive cerebellar atrophy in some cases. Additional rare subtypes (EA3 through EA9) have been described with varying genetic causes and clinical features. Treatment is primarily symptomatic and varies by subtype. Acetazolamide, a carbonic anhydrase inhibitor, is the mainstay of treatment for EA2 and can significantly reduce the frequency and severity of episodes in many patients. For EA1, carbamazepine or other anticonvulsants may be effective. Avoidance of known triggers is an important part of management. While episodic ataxia is not typically life-threatening, it can significantly impact quality of life, and some subtypes may be associated with progressive cerebellar dysfunction over time.

Common questions about Hereditary episodic ataxia